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doi:10.1016/j.kjms.2012.04.019Abstract Postmenopausal osteoporosis is commonly treated with alendronate, one of the bi-
sphosphonates used for the prevention and treatment of osteoporotic fractures. However, the
correlation between atypical femoral fractures and long-term bisphosphonate therapy has not
been clearly identified. We report here the case of a 69-year-old woman with postmenopausal
osteoporosis who presented with an atypical femoral subtrochanteric fracture on magnetic
resonance imaging (MRI) confirmation after having received alendronate therapy for about 3
years. The fracture united after refixation and after administration of alendronate was
stopped. Several published reports were reviewed, and some clinical characteristics of this
atraumatic fracture were revealed, including the clinical symptoms of thigh pain, stress reac-
tion or stress fracture, and transverse fracture with unicortical beak in an area of cortical
hypertrophy. In addition to a regular radiographic survey, MRI, which may provide early infor-
mation, and bone biopsy for pathologic analysis may be used as tools for early detection and
final diagnosis. Once an insufficiency fracture is suspected or proved to be related to bispho-
sphonate, the withholding of bisphosphonate should be highly recommended to enhanceof Orthopaedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Tzu-You
u.edu.tw (Y.-M. Cheng).
vier Taiwan LLC. All rights reserved.
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fracture occurred in the same areafracture healing. Prophylactic fixation should be considered if fracture healing is not good or if
the patient cannot tolerate protection of weight-bearing.
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Alendronate, one of the bisphosphonates, is a potent inhib-
itor of bone resorption, and is also prescribed as a first-line
therapy for postmenopausal osteoporosis [1]. In addition,
osteoporotic fractures may be prevented with alendronate.
Both clinically important as well as statistically significant
reductions in vertebral, nonvertebral, hip, and wrist frac-
tures have been observed with the use of alendronate at
10 mg/d for secondary prevention [2]. There is no consensus
on the duration of treatment [3]. However, in recent years,
reports on low-energy femoral subtrochanteric or shaft
fracture after long-term bisphosphonate use have been
published [4e11], although no significant increase in risk
associated with bisphosphonate use has been found in large-
scale studies [12,13]. In this article, we present the case of
a 69-year-old woman with a history of left atypical femoral
fracture after long-term alendronate therapy; the fracture
was confirmed by magnetic resonance imaging (MRI).Case report
Osteoporosis was diagnosed in a 55-year-old woman based on
a lumbar bone mineral density (BMD) survey (T-score e3.39)
at L2eL4, using Norland 36R dual-energy X-ray absorptiom-
etry (Fort Atkinson,WI, USA) in September 1995. Shehada20-
year history of bilateral knee osteoarthritis, as well as a
history of postmenopausal syndrome of about 9 years.
According to her medical records, she had histories
of glucosamine sulphate therapy for osteoarthritis and
medroxyprogesterone therapy for postmenopausalft proximal femoral shaft show
veals the same finding, which
.syndrome. She took a calcium supplement, due to lack of
reimbursement by health insurance.
In 2006, when she was 66 years old, she started taking
Fosamax (70mg alendronate acid) and a calcium supplement
once weekly. About 2 years after starting alendronate use,
she complained of left lateral thigh pain while walking. After
serial examinations, lesions at the hip joint and lumbar spine
as a cause of lateral thigh pain were excluded. Radiography
of the hip showed thickening of the cortex with a cleft at the
lateral cortex, which was suspected to be an insufficiency
fracture of the left proximal femoral shaft with callus
formation. An MRI study also confirmed the diagnosis of
insufficiency fracture with no other pathology (Fig. 1). She
had no other risk factor for pathologic fracture, including
cigarette smoking, corticosteroid usage, or history of
malignancy. Non-weight-bearingwas suggested at that time,
but the patient was not able to do this.
She visited the emergency department due to a sudden
onset of severe left hip pain with deformity while standing
up from a chair, about 3 years after the beginning of
alendronate use. No history of trauma or muscle weakness
was noted at that time. In the emergency department,
a radiograph of the left hip showed a left proximal femoral
transverse fracture in the subtrochanteric area with
displacement, which was compatible with a complete
fracture of the previous stress fracture (Fig. 2). No other
obvious bone lesion, including malignant change, was
noted. An intramedullary nail with locking screws was used
for fixation of the fracture. At the same time, a bone biopsy
was taken for pathologic examination, revealing dead bone
trabeculae with hemorrhage in the marrow spaces, which
further excluded the possibility of malignancy. The patient
was discharged without any complications. Alendronateing a radiolucent line and focal thickening of the lateral cortex.
indicates stress fracture. The subsequent femur insufficiency
Figure 2. Radiograph demonstrating a left subtrochanteric
fracture with displacement.
Femoral stress fracture after alendronate 557was withheld because of the suspicion of a possible
bisphosphonate-related stress fracture.
At the third month of follow-up, non-healing of the left
femur subtrochanteric fracture and a broken intra-
medullary nail were noted (Fig. 3). Internal fixation was
again performed, and the fracture united 3 months after
the second operation.Figure 3. (A) Subtrochanteric fracture of the left femur with in
nail. (B) Good union was shown 3 months after the second operatiDiscussion
Currently, bisphosphonates are the most popular anti-
resorptive agents available to treat osteoclast-mediated
bone resorption disease, including osteoporosis, Paget’s
disease, and metastatic bone disease [1]. Alendronate was
the first drug to be approved by the US Food and Drug
Administration in 1995, and it was reported to be well toler-
ated over a 10-year period [14]. When comparing daily
alendronate with placebo, BMD of the lumbar spine continu-
ously increased with alendronate use, and no association
between prolonged use of alendronate and an excess risk of
fracture was found [14].
However, recent studies suggest that long-term
bisphosphonate use may be related to low-energy sub-
trochanteric and femoral shaft fractures [4e8,10,11,15e17].
There have been a fewcases reported in Asian patients. In one
case report, a 72-year-old woman who had been taking
alendronate and calcium supplement therapy for 7 years
suffered a displaced transverse subtrochanteric femoral
fracture, andwasoperatedonto insert a longgammanail [18].
Similar to our case, she suffered from thigh pain for 1 year
before the fracture, and about 3 months postoperatively the
radiographs also showed signs of poor healing of the fracture.
Very fewstudieshave includedanMRI studythathasconfirmed
the diagnosis of insufficiency fracture. In our study, we per-
formed an MRI examination before the complete fracture of
the subtrochanteric region, which confirmed the diagnosis of
insufficiency fracture and excluded other pathologies.
In a study from Singapore, the researchers reviewed 17
patients who had undergone alendronate therapy for an
average of 4.8 years, and observed the typical fracture
configuration in all patients; this included (1) cortical
thickening of the lateral (tension) side of the subtrochanteric
region, (2) transverse fracture, and (3) a medial cortical
spike [6]. In another study, patients with femoral shaft
fractures who were taking alendronate were reviewed,
demonstrating an association between alendronate therapytramedullary nail fixation, showing poor healing with a broken
on.
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[7]. Similar results were characterized by a transverse frac-
ture with a unicortical beak in an area of cortical hyper-
trophy. The same fracture pattern was noted in our case.
These specific fracturepatternsmay result from theeffect of
a stress fracture, the impaired repair of which may be highly
suspected to be related to prolonged alendronate use.
Koh et al. demonstrated the cortical stress reactions
associated with prolonged antiresorptive therapy by
reviewing 32 patients who were receiving alendronate
therapy and who suffered from low-energy hip fracture
[19]. From the results, these authors concluded that, in the
presence of thigh pain, the “dreaded black line” on radio-
graphs revealed an increased risk for complete stress
fracture. In our case, the radiograph of the left proximal
femoral shaft before subtrochanteric fracture showed
a radiolucent line and focal thickening of the cortex, which
indicated a stress fracture. The stress reaction character-
ized by computed tomography and MRI [6] was reported,
and the same image was also noted on our patient’s MRI
before the complete fracture. The stress reaction detected
by MRI or radiography can be used as the portent of a low-
energy fracture related to alendronate. In particular, MRI
may be used in symptomatic patients taking alendronate
for the early detection and prevention of a fracture.
It seems that some specific patterns of insufficiency
fracture can be correlated with long-term bisphosphonate
therapy in Asian populations. The clinical symptom of thigh
pain of other than spinal or hip origin, and the stress reaction
or stress fractureonMRI or radiography,maybeused for early
detection of these insufficiency fractures. Even though
a causal relationship between alendronate use and femoral
insufficiency fracture has not yet been established [12,13],
we have to keep in mind the possible association between
alendronate and femoral insufficiency fracture if the thigh
pain cannot be identified as being of hip or spinal origin. It is
reasonable at that time to switch from bisphosphonate to an
alternative therapy for osteoporosis.
Once the insufficiency fracture is proved or suspected to
be related to bisphosphonate, stopping bisphosphonate
should be highly recommended to enhance fracture healing.
Prophylactic fixation should be considered if fracture healing
is not good or the patient cannot tolerate protection of
weight-bearing. In conclusion, femoral subtrochanteric
insufficiency fracture should be kept in mind when a patient
has taken a bisphosphonate for a long time and complains of
lateral thigh pain without an obvious hip or spinal lesion. An
MRI is of value in the diagnosis of such patients.References
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